PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Beck, D., Heiblig, M., Savic, S. orcid.org/0000-0001-7910-0554 et al. (12 more authors) (2025) PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome. In: Arthritis & Rheumatology. ACR Convergence 2025, 24-29 Oct 2025, Chicago, IL, USA. Vol. 77. Wiley, pp. 5163-5164. ISSN: 2326-5191. EISSN: 2326-5205.

Metadata

Item Type: Conference abstract
Authors/Creators:
  • Beck, D.
  • Heiblig, M.
  • Savic, S. ORCID logo https://orcid.org/0000-0001-7910-0554
  • Ferrada, M.
  • Mekinian, A.
  • Chowdhury, O.
  • Hammond, D.
  • Weeks, L.D.
  • Gurnari, C.
  • Kirino, Y.
  • Georgin-Lavialle, S.
  • Buckley, S.A.
  • Harder, B.G.
  • Goble, S.
  • Koster, M.
Dates:
  • Published (online): 4 December 2025
  • Published: 4 December 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Date Deposited: 23 Jul 2026 08:30
Last Modified: 23 Jul 2026 08:30
Published Version: https://acrjournals.onlinelibrary.wiley.com/doi/10...
Status: Published
Publisher: Wiley
Identification Number: 10.1002/art.43421
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)